MedMen Enterprises has agreed to acquire multistate medical marijuana company PharmaCann in an all-stock deal valued at $682 million, inking what is believed to be the largest acquisition to date in the U.S. cannabis industry. The deal will double the number of states where Los Angeles-based MedMen has licenses to operate – expanding the firm’s […]
Read MoreMarijuana Stocks & Public Companies
Navigating the marijuana sector: Q&A with Chris Hagedorn, GM of Scotts Miracle-Gro unit Hawthorne Gardening
If you’ve ever planted a garden or nurtured a lawn you’ve probably heard of Scotts Miracle-Gro. The Ohio company’s subsidiary, Hawthorne Gardening in Vancouver, Washington, has more recently helped cultivators with a trickier plant than carrots or Kentucky bluegrass: cannabis. Hawthorne’s rapid expansion has helped transform Scotts into a cannabis juggernaut from its early days […]
Read More
Weekly Deal Watch: Cannabis investor demand shifts from Canada to US
Canadian investors are turning their attention to the U.S., as multistate operators continue to build their infrastructure.
Read More
Canadian MJ producer Aurora Cannabis targets New York Stock Exchange listing
Canadian marijuana giant Aurora Cannabis has filed an application to list its shares on the New York Stock Exchange, a move that would make it the second major plant-touching company to trade on the Big Board – and the latest from Canada to establish roots on Wall Street. If approved, the Edmonton-based company could begin […]
Read More
Canadian cannabis companies bullish on US market, boosting cross-border acquisitions and deals
As marijuana companies across Canada brace for the historic rollout of the country’s recreational program next week, some businesses have their sights set on bigger opportunities they see coming in the United States. Canadian cannabis investment firms and holding companies are making multimillion-dollar bids on a range of U.S.-based cultivators, manufacturers and retailers already. Relatively […]
Read More
Chart: Canadian cannabis companies’ market caps rise into the 11 figures
Limited supply and red-hot demand for investment opportunities in Canada’s marijuana industry have caused stock prices and market capitalizations for cannabis companies to surge ahead of legal adult-use sales later this month. Market capitalizations of some of these companies in the Great White North now rival – or have even eclipsed – those of more […]
Read More
Cresco Labs closes $100 million raise, draws institutional investors to cannabis industry
Chicago-based marijuana firm Cresco Labs closed a $100 million funding round that attracted institutional investors, a notable milestone for cannabis finance in the United States. The raise represents the second-largest deal inked in the U.S. marijuana industry to date. New York-based Acreage Holdings’ $119 million raise in July holds the top spot for private funding […]
Read More
IHeartMedia to invest up to $10 million in marijuana publisher High Times
The nation’s largest radio broadcaster, IHeartMedia, has agreed to invest up to $10 million in the publisher of High Times magazine, giving the marijuana company access to the media firm’s digital and radio advertising platforms. Under the deal, IHeart will commit $5 million-$10 million worth of advertising on the internet and radio – platforms High […]
Read More
License suspension ‘stark reminder’ for Canadian marijuana companies
A licensed producer was suspended by Health Canada for the first time in four years, a sign that the government agency is keeping a closer eye on companies for potential violations ahead of this month’s launch of the nation’s recreational marijuana market. Health Canada notified Ontario-based Agrima Botanicals on Sept. 26 that it was suspending the […]
Read More
Cannabis edibles maker Dixie Brands raises $25M ahead of public stock listing in Canada
Infused cannabis products maker Dixie Brands closed a $25 million funding round as it works to go public in Canada before year’s end. The Series C capital raise was originally offered as a non-brokered private placement for up to $20 million, but heavy investor demand led Dixie to boost the offering to $25 million, the […]
Read More
CBD drugmaker GW Pharmaceuticals poised to raise $300 million
GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares. The London-based company’s announcement comes on the heels of the U.S. Drug Enforcement Administration’s move to take some cannabidiol products off the most restrictive class of controlled substances. That change will allow Epidiolex – a CBD drug manufactured by GW Pharmaceuticals to treat rare […]
Read MoreConference News
November/December Issue
Growing Ambition. Companies leverage capital, partnerships and diversification to expand beyond state lines.Read the Issue